Valneva (VALN)
(Delayed Data from NSDQ)
$7.87 USD
+0.37 (4.93%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $7.67 -0.20 (-2.54%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Market Cap
As of the previous market close, Valneva SE Sponsored ADR has a market cap of $638.21M, which represents its share price of $7.50 multiplied by its outstanding shares number of 85.09M. As a small-cap company, VALN's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
VALN 7.87 +0.37(4.93%)
Will VALN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VALN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VALN
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
VALN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Cooper Companies Q1 Earnings Likely to Reflect Seasonal Trends
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
Other News for VALN
Valneva (VALN) Partners with AGC Biologics for Shigella Vaccine Development
Valneva signs development, manufacturing agreement with AGC Biologics
AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's ...
MP Materials, CoreWeave, Trade Desk And Other Big Stocks Moving Higher On Tuesday
EMA Lifts Suspension on Valneva's (VALN) Chikungunya Vaccine for Seniors